J B Chemicals and Pharmaceuticals Ltd
JBCHEPHARM • Health Care
ROCE
24.75%
FY24 Actual
D/E Ratio
0.01
Zero Debt
5Y Rev CAGR
16.7%
High Growth
Profit Margin
16.4%
5Y Average
| Metrics (Values in Cr) | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM |
|---|---|---|---|---|---|---|
| Total Revenue | 2,154.9 | 2,463.47(+14.3%) | 3,159.22(+28.2%) | 3,521.45(+11.5%) | 3,956.31(+12.3%) | 4,255.69 |
| Operating Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Operating Profit | — | — | — | — | — | — |
| Raw Profit | 742.76 | 860.38(+15.8%) | 1,179.2(+37.1%) | 1,228.9(+4.2%) | 1,316.97(+7.2%) | — |
| Operating Expenses | 102.59 | 150.79(+47.0%) | 190.53(+26.4%) | 166.96(-12.4%) | 238.69(+43.0%) | 3,060.31 |
| Selling General And Administrative Expenses | 233.56 | 358.9(+53.7%) | 448.81(+25.1%) | 501.94(+11.8%) | 558.92(+11.4%) | — |
| Depreciation And Amortization | 68.67 | 72.66(+5.8%) | 114.41(+57.5%) | 138.32(+20.9%) | 171.04(+23.7%) | 178.93 |
| Profit Before Interest | 604.12 | 510.03(-15.6%) | 591.28(+15.9%) | 795.84(+34.6%) | 899.13(+13.0%) | 1,016.45 |
| Interest Expense | 7.24 | 5.12(-29.3%) | 36.05(+604.1%) | 44.33(+23.0%) | 11.73(-73.5%) | 5.79 |
| Profit Before Tax | 596.88 | 504.91(-15.4%) | 555.23(+10.0%) | 751.51(+35.4%) | 887.4(+18.1%) | 1,010.66 |
| Tax Expense | 148.92 | 119.54(-19.7%) | 145.4(+21.6%) | 198.88(+36.8%) | 227.8(+14.5%) | 256.88 |
| Net Income | 447.96 | 385.37(-14.0%) | 409.83(+6.3%) | 552.63(+34.8%) | 659.6(+19.4%) | 753.78 |
| Earnings Per Share | 28.982 | 24.933(-14.0%) | 26.499(+6.3%) | 35.659(+34.6%) | 42.435(+19.0%) | 48.419 |
| Dividends Per Share | 8.25 | 8.25(0.0%) | 8.875(+7.6%) | 12.25(+38.0%) | 15.5(+26.5%) | 15.5 |
| Payout Ratio | 0.285 | 0.331(+16.2%) | 0.335(+1.2%) | 0.344(+2.6%) | 0.365(+6.3%) | 0.32 |